Why IMU is a multi multi bagger, page-11598

First 11598 Last

Share
Profile

Follow
SENARIS

2,922 Posts.

132

23/02/23

19:59

Post #: 66430367
Share

Originally posted by fourdollars: ↑

"Here is the view of the boards of all 3 comps and I refer to the 3 as all hired scientists and experts have agreed to Hoppers way as this is the best way to succeed in oncology."

Hopper's way is to have raised approx: $750m across Viralytics, Imugene, Radiopharm, Prescient, Arovella and Chimeric and returned $500m to the owners of Viralytics. So his biotech career is negative $250m to date.

Of course its far worse for retail investors because Hopper and his mates never pay retail for their shares, so they haven't made a proportional contribution to the $750m but they have received a much larger proportion of the $500m that was returned.

Exactly none of his products have been successful in oncology to date. Not a single product has been commercialised - in fact I don't think any have even reached a Phase 3 trial. Please consider this when you make completely unfounded comments like the one above.

For the record, I'm not blaming him for the failure of Viralytics to be commercialised, but the one technology he was successful in selling to BP ended up shelved, so its not going to have a positive effect on his other drugs.

The main reason all those scientists and experts join the Hopper team is money. He pays heaps of it (way too much in fact) and gives them a platform that they would not otherwise have in BP land.

Its a successful approach if you are Hopper. Not so much if you are a retail investor (unless you have been lucky or expert in trading).

Expand

"Exactly none of his products have been successful in oncology to date. Not a single product has been commercialised"

"The main reason all those scientists and experts join the Hopper team is money."

So so true

IMU Price at posting: 13.5¢ Sentiment: None Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

AI stocks: What to expect in 2024-25

There are more pages in this discussion • 13,868 more messages in this thread...

First 11598 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.5¢		Change 0.000(0.00%)		Mkt cap ! $404.2M

Open	High	Low	Value	Volume
5.6¢	5.6¢	5.5¢	$399.1K	7.236M

Buyers (Bids)

No.	Vol.	Price($)
3	201018	5.5¢

Sellers (Offers)

Price($)	Vol.	No.
5.6¢	749859	7

View Market Depth

No.	Vol.	Price($)
3	201018	0.055
17	2191168	0.054
11	800647	0.053
19	1659549	0.052
18	2560434	0.051

Price($)	Vol.	No.
0.056	749859	7
0.057	270444	2
0.058	725000	4
0.059	961714	3
0.060	888850	11

Last trade - 16.10pm 17/07/2024 (20 minute delay)

IMU (ASX) Chart

Why IMU is a multi multi bagger, page-11598

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

AI stocks: What to expect in 2024-25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why IMU is a multi multi bagger, page-11598

Top Stories

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

AI stocks: What to expect in 2024-25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News